World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
43243
World Ranking
15359
National Ranking
7745

Patrick A. Ott publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Patrick A. Ott sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 344 publications — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Patrick A. Ott D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Patrick A. Ott sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Patrick A. Ott is affiliated with Harvard University in the United States. Their research primarily spans the field of Medicine, with a focus on Oncology, Immunology, Molecular Biology, Epidemiology, and Pulmonary and Respiratory Medicine. The main topics of their work include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, vaccines and immunoinformatics approaches, Cutaneous Melanoma Detection and Management, and Cancer Genomics and Diagnostics.

Ott has contributed to several recent papers in high-impact journals. These include:

  • Advances in the development of personalized neoantigen-based therapeutic cancer vaccines, 2021, Nature Reviews Clinical Oncology
  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer, 2020, Cell
  • Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma, 2021, Nature
  • Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma, 2021, Nature Medicine
  • NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021, 2021, Journal of the National Comprehensive Cancer Network

Their frequent co-authors include:

  • Elizabeth I. Buchbinder
  • F. Stephen Hodi
  • Anita Giobbie-Hurder
  • Osama E. Rahma
  • Catherine J. Wu

Ott regularly publishes in several venues with the highest number of publications appearing in the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Cancer Research, Regular and Young Investigator Award Abstracts, and Nature.

Their research topics and fields indicate a strong emphasis on innovative cancer treatments, especially related to immunotherapy. Their involvement in neoantigen vaccine development and personalized therapies reflects a focus on targeted cancer treatment strategies.

Best Publications

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • An immunogenic personal neoantigen vaccine for patients with melanoma

    Patrick A. Ott;Zhuting Hu;Derin B. Keskin;Derin B. Keskin;Sachet A. Shukla;Sachet A. Shukla

  • Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    Razvan Cristescu;Robin Mogg;Mark Ayers;Andrew Albright

  • A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

    Livnat Jerby-Arnon;Parin Shah;Michael S. Cuoco;Christopher Rodman

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

    Derin B. Keskin;Annabelle J. Anandappa;Jing Sun;Itay Tirosh

  • Towards personalized, tumour-specific, therapeutic vaccines for cancer

    Zhuting Hu;Patrick A. Ott;Patrick A. Ott;Catherine J. Wu

  • Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    F Stephen Hodi;Jason Chesney;Anna C Pavlick;Caroline Robert

  • CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

    Patrick A. Ott;F. Stephen Hodi;Caroline Robert

  • T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    Patrick A. Ott;Yung Jue Bang;Sarina A. Piha-Paul;Albiruni R. Abdul Razak

  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

    Padmanee Sharma;Margaret K. Callahan;Petri Bono;Joseph Kim

  • Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

    Douglas B. Johnson;Ryan J. Sullivan;Patrick A. Ott;Matteo S. Carlino

  • Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

    Eryn Blass;Patrick A. Ott

  • A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

    Patrick A. Ott;Siwen Hu-Lieskovan;Bartosz Chmielowski;Ramaswamy Govindan

  • Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors

    Frank B. Cortazar;Kristen A. Marrone;Megan L. Troxell;Kenneth M. Ralto

  • CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

    Yelena Y. Janjigian;Johanna Bendell;Emiliano Calvo;Joseph W. Kim

  • Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    Kevin B. Kim;Richard Kefford;Anna C. Pavlick;Jeffrey R. Infante

  • Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.

    Lucie Heinzerling;Patrick A. Ott;F. Stephen Hodi;Aliya N. Husain

  • Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

    Patrick A. Ott;Elena Elez;Sandrine Hiret;Dong Wan Kim

  • Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results from the KEYNOTE-028 Study

    Patrick A. Ott;Yung Jue Bang;Dominique Berton-Rigaud;Elena Elez

Frequent Co-Authors

F. Stephen Hodi
F. Stephen Hodi Harvard University
Johanna C. Bendell
Johanna C. Bendell Sarah Cannon Research Institute
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Jason J. Luke
Jason J. Luke University of Pittsburgh
Sarina Anne Piha-Paul
Sarina Anne Piha-Paul The University of Texas MD Anderson Cancer Center
Catherine J. Wu
Catherine J. Wu Harvard University
Sachet A. Shukla
Sachet A. Shukla The University of Texas MD Anderson Cancer Center
Nina Bhardwaj
Nina Bhardwaj Icahn School of Medicine at Mount Sinai
Nir Hacohen
Nir Hacohen Harvard University
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean attending traditional medical school. There are many alternative healthcare roles that offer flexibility and strong job prospects through online study.

For those interested in the administrative side of healthcare, billing and coding classes online can open doors to essential healthcare support positions. These courses are ideal for students who prefer remote work opportunities and wish to start working quickly.

If patient care is your goal, a variety of affordable online nursing programs are available, letting you train for roles as a registered nurse without relocating. Nurses seeking advanced roles can pursue affordable np programs to gain greater autonomy and increased earning potential.

For aspiring nurse leaders or educators, an online phd nursing offers a pathway to the highest levels in the field, supporting careers in research, teaching, and advanced clinical practice.

Each of these online degree options broadens your career outlook, providing opportunities both in direct patient care and essential support services within the U.S. healthcare system.

Best Scientists Citing Patrick A. Ott

Trending Scientists

Recently Published Articles